Verrica Pharmaceuticals Inc. (VRCA) financial statements (2021 and earlier)

Company profile

Business Address 10 NORTH HIGH STREET
WEST CHESTER, PA 19380
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments91120241038103
Cash and cash equivalents91120241038103
Other undisclosed current assets5663606081601
Total current assets:657480859199105
Noncurrent Assets
Operating lease, right-of-use asset00  
Property, plant and equipment2211000
Deposits noncurrent assets1000000
Other undisclosed noncurrent assets  00   
Total noncurrent assets:3221100
TOTAL ASSETS:687681869299105
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3443223
Accounts payable1111111
Accrued liabilities2332212
Debt00     
Due to related parties  0 000
Other undisclosed current liabilities  00   
Total current liabilities:3443223
Noncurrent Liabilities
Long-term debt and lease obligation00     
Operating lease, liability00  
Other undisclosed noncurrent liabilities  00   
Total noncurrent liabilities:0000   
Total liabilities:3443223
Stockholders' equity
Stockholders' equity attributable to parent657277838996102
Common stock0000000
Additional paid in capital127125124123123123122
Accumulated other comprehensive income (loss)0000(0)(0) 
Accumulated deficit(61)(54)(47)(40)(33)(27)(20)
Stockholders' equity note, subscriptions receivable(0)      
Total stockholders' equity:657277838996102
TOTAL LIABILITIES AND EQUITY:687681869299105

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(8)(7)(8)(8)(7)(7)(6)
Other operating expense, net
(Other Expenses)
(0) (0)  (0) 
Other undisclosed operating income0 0  0 
Operating loss:(8)(7)(8)(8)(7)(7)(6)
Nonoperating income0011100
Investment income, nonoperating0011100
Net loss available to common stockholders, diluted:(8)(6)(7)(7)(6)(7)(6)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(8)(6)(7)(7)(6)(7)(6)
Comprehensive loss:(8)(6)(7)(7)(6)(7)(6)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)00(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(8)(6)(7)(7)(6)(7)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: